PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
D'Avino, P.* ; Kim, J.* ; Li, M.* ; Gessner, P.* ; Westermann, P.* ; Pat, Y.* ; Beha, C.* ; Traidl-Hoffmann, C. ; Bost, J.* ; Gaudenzio, N.* ; Messner, C.B.* ; Akdis, C.A.* ; Mitamura, Y.*

Distinct roles of IL-4, IL-13, and IL-22 in human skin barrier dysfunction and atopic dermatitis.

Allergy, DOI: 10.1111/all.70060 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Atopic dermatitis (AD) is a chronic type-2 inflammatory skin disease characterized by eczema and epithelial barrier dysfunction. Along with the type-2 cytokines IL-4 and IL-13, IL-22 contributes to AD pathogenesis. To date, most skin studies rely on reconstructed keratinocytes, which do not represent the real skin response. OBJECTIVE: Here, we report the distinct effects of IL-4, IL-13, and IL-22 on bio-stabilized human skin with intact barriers and immune cells. METHODS: Spatial transcriptomics on AD-lesions and non-lesional skin was performed. Ex vivo skin barrier integrity was evaluated using electrical impedance spectroscopy (EIS), RNA-sequencing, and untargeted proteomics, complemented by analyses of skin biopsies from dupilumab-treated AD patients. RESULTS: Spatial transcriptomics demonstrated that AD lesions showed reduced expression of key barrier genes, including CLDN1, FLG, and FLG2. IL-4, IL-13, and IL-22 disrupted the skin barrier in the ex vivo human skin. Combining type-2 cytokines and IL-22 alone downregulated genes critical for barrier function and keratinization. In addition, IL-4 and IL-13 downregulated antimicrobial peptides, while IL-22 upregulated them. Interestingly, IL-4 and IL-13 reduced IL-22Rα1, and IL-22 upregulated IL-4Rα, suggesting immune cross-regulation. Proteomic analysis confirmed that all three cytokines (IL-4, IL-13, and IL-22) reduced the expression of key skin barrier proteins, particularly filaggrin and claudin-1. Dupilumab treatment of AD patients for 3 months restored IL-4/IL-13-dysregulated genes, whereas it had limited effect on IL22-associated pathways. CONCLUSION: This comprehensive study provides insights into the distinct immune profiles following IL-4, IL-13, and IL-22 stimulation on human skin, highlighting their complex interplay in disrupting skin barrier function and modulating innate immune responses.
Impact Factor
Scopus SNIP
Altmetric
12.000
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Atopic Dermatitis ; Dupilumab (anti‐il4rα Antibody) ; Electrical Impedance Spectroscopy ; Ex Vivo Human Skin ; Inflammation ; Interleukin‐13 ; Interleukin‐22 ; Interleukin‐4 ; Skin Barrier; Cytokine; T(h)17; Inflammation; Activation; Cells
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0105-4538
e-ISSN 1398-9995
Zeitschrift Allergy
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Environmental Medicine (IEM)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Allergy
PSP-Element(e) G-503400-001
Förderungen This work was funded by SciBase AB, GenoSkin SAS, and the Swiss National Foundation. SciBase AB contributed EIS instruments and electrodes for the study and contributed toward study funding. Genoskin SAS provided NativeSkin samples for the study with spec
DOI 10.1111/all.70060
WOS ID 001576265600001
Scopus ID 105016866643
PubMed ID 40985485
Erfassungsdatum 2025-10-21
[➜Korrektur melden]